December 27, 2022In order to further expand overseas markets and meet the needs of the company's strategic development, Beilu Pharmaceutical intends to establish a wholly-owned subsidiary in Hong Kong.Actively exp...view
May 13, 2021For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of the body's local tissues.view
February 1, 2023Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...view
September 21, 2023Beilu Pharmaceutical's subsidiary, Zhejiang Hichi Pharmaceutical, has recently obtained the certificate of registration for Iohexol API from the Ministry of Food and Drug Safety in Korea.This regi...view
July 27, 2021Recently, our company received the“Drug Supplementary Application Approval Notice”(Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection.view
October 27, 2021Non ionic contrast medium is the second generation of CT contrast medium. Compared with the first generation of ionic contrast medium, the non ionic contrast medium has greater water solubility. In ad...view